These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 10818128)

  • 1. The plasmin system is induced by and degrades amyloid-beta aggregates.
    Tucker HM; Kihiko M; Caldwell JN; Wright S; Kawarabayashi T; Price D; Walker D; Scheff S; McGillis JP; Rydel RE; Estus S
    J Neurosci; 2000 Jun; 20(11):3937-46. PubMed ID: 10818128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impacts of aging and amyloid-β deposition on plasminogen activators and plasminogen activator inhibitor-1 in the Tg2576 mouse model of Alzheimer's disease.
    Bi Oh S; Suh N; Kim I; Lee JY
    Brain Res; 2015 Feb; 1597():159-67. PubMed ID: 25454795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urokinase-Type Plasminogen Activator Protects Cerebral Cortical Neurons from Soluble Aβ-Induced Synaptic Damage.
    Diaz A; Merino P; Guo JD; Yepes MA; McCann P; Katta T; Tong EM; Torre E; Rangaraju S; Yepes M
    J Neurosci; 2020 May; 40(21):4251-4263. PubMed ID: 32332118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue plasminogen activator requires plasminogen to modulate amyloid-beta neurotoxicity and deposition.
    Tucker HM; Kihiko-Ehmann M; Wright S; Rydel RE; Estus S
    J Neurochem; 2000 Nov; 75(5):2172-7. PubMed ID: 11032907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urokinase-type plasminogen activator inhibits amyloid-beta neurotoxicity and fibrillogenesis via plasminogen.
    Tucker HM; Kihiko-Ehmann M; Estus S
    J Neurosci Res; 2002 Oct; 70(2):249-55. PubMed ID: 12271474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration.
    Melchor JP; Pawlak R; Strickland S
    J Neurosci; 2003 Oct; 23(26):8867-71. PubMed ID: 14523088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade.
    Jacobsen JS; Comery TA; Martone RL; Elokdah H; Crandall DL; Oganesian A; Aschmies S; Kirksey Y; Gonzales C; Xu J; Zhou H; Atchison K; Wagner E; Zaleska MM; Das I; Arias RL; Bard J; Riddell D; Gardell SJ; Abou-Gharbia M; Robichaud A; Magolda R; Vlasuk GP; Bjornsson T; Reinhart PH; Pangalos MN
    Proc Natl Acad Sci U S A; 2008 Jun; 105(25):8754-9. PubMed ID: 18559859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Small Molecule Inhibitor of Plasminogen Activator Inhibitor-1 Reduces Brain Amyloid-β Load and Improves Memory in an Animal Model of Alzheimer's Disease.
    Akhter H; Huang WT; van Groen T; Kuo HC; Miyata T; Liu RM
    J Alzheimers Dis; 2018; 64(2):447-457. PubMed ID: 29914038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urokinase-Type Plasminogen Activator Triggers Wingless/Int1-Independent Phosphorylation of the Low-Density Lipoprotein Receptor-Related Protein-6 in Cerebral Cortical Neurons.
    Diaz A; Martin-Jimenez C; Woo Y; Merino P; Torre E; Yepes M
    J Alzheimers Dis; 2022; 89(3):877-891. PubMed ID: 35964187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The plasminogen activating system in the pathogenesis of Alzheimer's disease.
    Yepes M
    Neural Regen Res; 2021 Oct; 16(10):1973-1977. PubMed ID: 33642369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The possible role of tissue-type plasminogen activator (tPA) and tPA blockers in the pathogenesis and treatment of Alzheimer's disease.
    Melchor JP; Pawlak R; Chen Z; Strickland S
    J Mol Neurosci; 2003; 20(3):287-9. PubMed ID: 14501010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aβ delays fibrin clot lysis by altering fibrin structure and attenuating plasminogen binding to fibrin.
    Zamolodchikov D; Strickland S
    Blood; 2012 Apr; 119(14):3342-51. PubMed ID: 22238323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of plasminogen activation protects against ganglion cell loss in a mouse model of retinal damage.
    Zhang X; Chaudhry A; Chintala SK
    Mol Vis; 2003 Jun; 9():238-48. PubMed ID: 12813409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta-amyloid (Abeta) causes detachment of N1E-115 neuroblastoma cells by acting as a scaffold for cell-associated plasminogen activation.
    Kranenburg O; Bouma B; Gent YY; Aarsman CJ; Kayed R; Posthuma G; Schiks B; Voest EE; Gebbink MF
    Mol Cell Neurosci; 2005 Mar; 28(3):496-508. PubMed ID: 15737740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gonadotropin surge-induced up-regulation of the plasminogen activators (tissue plasminogen activator and urokinase plasminogen activator) and the urokinase plasminogen activator receptor within bovine periovulatory follicular and luteal tissue.
    Dow MP; Bakke LJ; Cassar CA; Peters MW; Pursley JR; Smith GW
    Biol Reprod; 2002 May; 66(5):1413-21. PubMed ID: 11967205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyloid-beta-stimulated plasminogen activation by tissue-type plasminogen activator results in processing of neuroendocrine factors.
    Kranenburg O; Gent YY; Romijn EP; Voest EE; Heck AJ; Gebbink MF
    Neuroscience; 2005; 131(4):877-86. PubMed ID: 15749342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasminogen activator-plasmin system potentiates the proliferation of hepatocytes in primary culture.
    Akao M; Hasebe Y; Okumura N; Hagiwara H; Seki T; Ariga T
    Thromb Res; 2002 Aug; 107(3-4):169-74. PubMed ID: 12431485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue-type plasminogen activator is a multiligand cross-beta structure receptor.
    Kranenburg O; Bouma B; Kroon-Batenburg LM; Reijerkerk A; Wu YP; Voest EE; Gebbink MF
    Curr Biol; 2002 Oct; 12(21):1833-9. PubMed ID: 12419183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid-beta levels are significantly reduced and spatial memory defects are rescued in a novel neuroserpin-deficient Alzheimer's disease transgenic mouse model.
    Fabbro S; Schaller K; Seeds NW
    J Neurochem; 2011 Sep; 118(5):928-38. PubMed ID: 21689108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains.
    Ledesma MD; Da Silva JS; Crassaerts K; Delacourte A; De Strooper B; Dotti CG
    EMBO Rep; 2000 Dec; 1(6):530-5. PubMed ID: 11263499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.